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Induced pluripotent stem cells (iPSCs) can be generated 
from patients with specific diseases by the transduction 
of reprogramming factors and can be useful as a cell 
source for cell transplantation therapy for various dis-
eases with impaired organs. However, the low efficiency 
of iPSC derived from somatic cells (0.01–0.1%) is one 
of the major problems in the field. The phosphoinosit-
ide 3-kinase (PI3K) pathway is thought to be impor-
tant for self-renewal, proliferation, and maintenance of 
embryonic stem cells (ESCs), but the contribution of this 
pathway or its well-known negative regulator, phospha-
tase, and tensin homolog deleted on chromosome ten 
(Pten), to somatic cell reprogramming remains largely 
unknown. Here, we show that activation of the PI3K 
pathway by the Pten inhibitor, dipotassium bisperoxo(5-
hydroxypyridine-2-carboxyl)oxovanadate, improves the 
efficiency of germline-competent iPSC derivation from 
mouse somatic cells. This simple method provides a new 
approach for efficient generation of iPSCs.
Received 28 November 2012; accepted 3 March 2013; advance online  
publication 9 April 2013. doi:10.1038/mt.2013.60
INTRODUCTION
Mammalian somatic cells can be reprogrammed into induced plu-
ripotent stem cells (iPSCs) by ectopic expression of Oct3/4 (also 
known as Pou5f1), Klf4, and Sox2 with or without c-Myc (hereaf-
ter referred to as “OKSM” and “OKS”, respectively).1–4 iPSCs are 
similar to embryonic stem cells (ESCs) in their morphology, gene 
expression, and ability to differentiate into the three germ layers 
in vitro and in vivo.1,5 Compared with ESCs, iPSCs avoid ethical 
controversy and immune rejection and have a great potential to 
be a cell source for personalized stem cell-based transplantation 
therapies. However, the efficiency of iPSC generation is quite low 
(0.01–0.1%), which is one of the obstacles to be overcome.1–4,6,7 
This low efficiency of iPSC generation is considered to be partially 
due to senescence and apoptosis induced by ectopic expression of 
OKSM,8 although the molecular mechanisms involved in somatic 
cell reprogramming have not been fully elucidated.1–3,7 Thus, 
understanding of the molecular mechanisms leading to repro-
gramming of somatic cells is crucial, and development of a new 
strategy for efficient iPSC generation is strongly desired.8
Numerous studies have shown that the phosphoinositide 
3-kinase (PI3K) signaling pathway is required for maintenance of 
ESC pluripotency by regulating Nanog and Sox2, both of which 
are transcription factors involved in self-renewal of ESCs.9–12 In 
addition, the PI3K pathway is known to be negatively regulated 
by phosphatase and tensin homolog deleted on chromosome ten 
(Pten), a well-known tumor suppressor that is deleted or mutated 
in various types of cancer.13–16 Recent studies have shown that 
knockdown of Pten in ESCs promotes self-renewal, as well as cell 
survival and proliferation,16–18 indicating that Pten is also involved 
in the control of stem cell behavior through PI3K regulation.
Here, we report that transient inhibition of Pten by its inhibi-
tor during the process of reprogramming mouse embryonic 
fibroblasts (MEFs) promotes their proliferation and enhances 
the efficiency of germline-competent iPSC generation by ectopic 
expression of OKSM.
RESULTS
To examine whether inhibition of Pten facilitates the reprogram-
ming process for iPSC generation, we first retrovirally transduced 
OKSM into MEFs lacking Pten (Pten−/− MEFs)19 and cultured these 
cells on mitomycin C (MMC)-treated SNL feeders (a SIM mouse 
embryo-derived thioguanine and ouabain resistant (STO) cell line 
transformed with neomycin resistance and mouse leukemia inhibi-
tory factor genes) in mouse ESC medium. At about 7 days after 
OKSM transduction into Pten−/− MEFs, ESC-like round-shaped 
colonies were observed (Figure 1a). We examined the expression 
of stage-specific mouse embryonic antigen1 (SSEA1), a marker of 
mouse ESCs, by immunocytochemistry (Figure 1b,c).20 The num-
ber of SSEA1+ colonies induced by OKSM significantly increased 
in Pten−/− MEF cultures (103 ± 2) compared with that in Pten+/− and 
wild-type MEF cultures (40 ± 9 and 21 ± 9, respectively; Figure 1c, 
Inhibition of PTEN Tumor Suppressor Promotes 
the Generation of Induced Pluripotent Stem Cells
Jiyuan Liao1, Tomotoshi Marumoto1,2, Saori Yamaguchi1, Shinji Okano3, Naoki Takeda4, Chika Sakamoto1, 
Hirotaka Kawano1, Takenobu Nii1, Shohei Miyamato1, Yoko Nagai1, Michiyo Okada1, Hiroyuki Inoue1,2, 
Kohichi Kawahara5, Akira Suzuki5, Yoshie Miura1 and Kenzaburo Tani1,2
1Division of Molecular and Clinical Genetics, Department of Molecular Genetics, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan; 
2Department of Advanced Molecular and Cell Therapy, Kyushu University Hospital, Fukuoka, Japan; 3Division of Pathophysiological and Experimental 
Pathology, Department of Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; 4Division of Transgenic Technology, 
 Center for Animal Resources and Development, Kumamoto University, Kumamoto, Japan; 5Division of Cancer Genetics, Department of Molecular 
 Genetics, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan
1242
1250
Inhibition of PTEN Improves iPSC Generation
Molecular Therapy
10.1038/mt.2013.60
original article
9April2013
21
6
28November2012
3March2013
The first two authors contributed equally to this work.
Correspondence: Kenzaburo Tani, Division of Molecular and Clinical Genetics, Department of Molecular Genetics, Medical Institute of Bioregulation, 
Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812–8582, Japan. E-mail: taniken@bioreg.kyushu-u.ac.jp
© The American Society of Gene & Cell Therapy
1242 www.moleculartherapy.org vol. 21 no. 6, 1242–1250 june 2013
© The American Society of Gene & Cell Therapy
Inhibition of PTEN Improves iPSC Generation
left panel). Similar results were obtained when OKS were trans-
duced (15 ± 4 for Pten−/− MEFs, 6 ± 2 for Pten+/− MEFs and 2 ± 1 for 
wild-type MEFs; Figure 1c, right panel).
To confirm that SSEA1+ colonies were derived from a single cell, 
and not from cell clusters, we replated fewer OKSM-transduced 
Pten−/− MEFs onto MMC-treated SNL feeders (100 cells per well in 
a six-well plate) in ESC medium. At 14 days after retroviral trans-
duction, the number of alkaline phosphatase-positive (AP+) colo-
nies was counted. As a result, 71 ± 12 AP+ colonies were generated 
from Pten−/− MEFs, whereas only 8 ± 1 colonies were generated 
from wild-type MEFs (Figure 1d, left panel), indicating that ~70% 
of OKSM-transduced Pten−/− MEFs had the potential to become 
iPSCs. Similar results were obtained when OKS were transduced 
into Pten−/− MEFs (Figure 1d, right panel). These results strongly 
indicated that the deficiency of Pten significantly increased the 
number of iPSCs generated by transduction of OKSM or OKS.
Loss of Pten has been shown to activate the PI3K-Akt path-
way.13,21 We next activated the PI3K pathway by expression of 
phosphatase-deficient Pten mutants that contained a Cys-124 to 
serine substitution at the phosphatase catalytic center (CS-Pten),22 
or the active myristoylated form of Akt (myr-Akt),23 and then the 
efficiency of iPSC generation from wild-type MEFs by OKSM 
transduction was examined. We observed significantly more AP+ 
colonies generated from MEFs expressing CS-Pten+OKSM or 
myr-Akt+OKSM compared with those generated from the control 
(354 ± 41, 355 ± 10 and 231 ± 25, respectively) (Figure 2a). These 
results indicated that activation of the PI3K pathway in MEFs 
enhanced the generation of iPSCs by co-expression of OKSM.
It is thought that continuous activation of the PI3K pathway 
may cause transformation of cells.24 Therefore, to efficiently and 
safely generate iPSCs, transient activation of the PI3K pathway com-
bined with transduction of OKSM might be desirable. To establish 
transient activation of the PI3K pathway, we used a Pten inhibitor, 
dipotassium bisperoxo(5-hydroxypyridine-2-carboxyl)oxovanadate 
[bpV(HOpic)],25 during the process of iPSC generation (from day 0 
to 10 after transduction) (Figure 2b). The bpV(HOpic) concentra-
tion was considered optimal at 100 nmol/l, which was determined 
by analyzing the activation status of Akt in MEFs by western blot-
ting (Supplementary Figure S1 and Supplementary Materials 
and Methods). MEFs cultured in medium containing 100 nmol/l 
bpV(HOpic) were transduced with OKSM, resulting in genera-
tion of ESC-like colonies (bpV-iPSCs) on day 14 after transduction 
(Figure 2b,e, left panel). After isolation of these ESC-like colonies 
on day 14 after transduction, eight bpV-iPSC lines were established 
and expanded in conventional ESC medium on SNL feeders and 
then characterized further (Supplementary Table S1). Reverse tran-
scription PCR showed that all of the bpV-iPSC lines examined (8/8) 
expressed ESC markers such as endogenous Oct3/4, Sox2, and Nanog 
(Figure 2d). In addition, bpV-iPSC lines were positive for AP activ-
ity and SSEA1 staining (Figure 2e, middle and right panels, respec-
tively). It should be noted that the efficiency of iPSC generation from 
OKSM-transduced MEFs in the presence of bpV(HOpic) was much 
higher than that from the untreated control (353 ± 42 versus 189 ± 32; 
Figure 2c, left panel). Furthermore, inhibition of the PI3K pathway 
by LY294002,26 a reversible inhibitor of all classes of PI3Ks, resulted 
in a sharp decrease of the efficiency of iPSC generation (20 ± 11; 
Figure 2c, left panel). Similar results were obtained when OKS were 
transduced in the presence of bpV(HOpic) (89 ± 11 versus 60 ± 5; 
Figure 2c, right panel). Moreover, the emergence of SSEA1+ colonies 
from MEFs transduced with OKSM was enhanced by bpV(HOpic) 
treatment (n = 3, P < 0.05; Supplementary Figure S2).
These results were further confirmed by experiments using MEFs 
carrying the green fluorescent protein (GFP) gene under the control 
of the Nanog promoter (Nanog-GFP MEFs).12 We found that tran-
sient treatment with bpV(HOpic) significantly increased the num-
ber of  Nanog-GFP+ colonies from MEFs  transduced with OKSM 
or OKS under a feeder-free condition (n > 3, P < 0.05; Figure 3a). 
These results strongly indicated that inhibition of Pten promoted the 
efficiency of iPSC generation by transduction of OKSM or OKS.
Figure 1 Loss of Pten promotes reprogramming of MEFs into 
iPSCs. (a) Representative image of an iPSC colony derived from 
Pten−/− MEFs by transduction of mouse OKSM. Scale bar = 100 μm. (b) 
Immunocytochemical staining of SSEA1 on iPSCs induced by transduc-
tion of OKSM into Pten−/− MEFs. Scale bar = 0.2 mm. (c) Counts of SSEA1+ 
colonies. A total of 5,000 (OKSM) or 50,000 (OKS) retrovirally trans-
duced MEFs with Pten+/+, Pten+/−, or Pten−/− genotypes were transferred 
onto feeders on day 4 after transduction. SSEA1+ colonies were counted 
on day 14 (OKSM, left) and day 28 (OKS, right) after transduction. Data 
are the mean ± SD (n = 3), *P < 0.05 versus wild type. (d) Counts of AP+ 
colonies derived from single cells. A total of 100 MEFs (OKSM or OKS) 
with Pten+/+, Pten+/−, or Pten−/− genotypes were transferred onto feed-
ers on day 4 after transduction. AP+ colonies generated from Pten+/+, 
Pten+/−, or Pten−/− MEFs transduced with OKSM (left) or OKS (right) were 
counted on day 12 (OKSM) and day 28 (OKS) after transduction. Data 
are the mean ± SD (n = 3 or more), *P < 0.05 versus wild type. iPSC, 
induced pluripotent stem cell; MEF, mouse embryonic fibroblast.
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It has been reported that the use of PS48, a small molecule 
activator of 3′-phosphoinositide–dependent kinase-1 (PDK1) 
that is involved in the PI3K pathway, can enhance the repro-
gramming efficiency for iPSC generation from human cells.27 
We therefore examined whether bpV(HOpic) or PS48 could 
further enhance the reprogramming efficiency. We found that a 
significantly higher number of AP+ colonies were formed from 
bpV(HOpic)-treated MEFs compared with that from PS48-
treated MEFs (n = 3, P < 0.05; Supplementary Figure S3), indi-
cating that inhibition of Pten by bpV(HOpic) might be a better 
approach than activation of PDK1 by PS48 for the enhancement 
of reprogramming.
To exclude the possibility that nonspecific effects of 
bpV(HOpic) had affected the iPSC generation, we also tested 
other specific Pten inhibitors such as SF1670 and bpV(Phen). 
As a result, the number of AP+ colonies appeared to significantly 
increase on day 10 after transduction in the presence of SF1670 or 
bpV(Phen) (Supplementary Figure S4).
It has been reported that various kinds of chemicals and 
supplements, such as histone deacetylase inhibitors, valproic 
acid (VPA), MAPK/ERK kinase inhibitors + glycogen synthase 
kinase 3β (GSK3β) inhibitors (2i), and vitamin C (Vc), enhance 
the reprogramming efficiency of somatic cells into iPSCs.6,28–30 
Therefore, various combinations of bpV(HOpic) were tested with 
these compounds, such as bpV(HOpic)+Vc, bpV(HOpic)+2i, and 
bpV(HOpic)+VPA. We found that combined use of bpV(HOpic) 
with each compound significantly increased the number of AP+ or 
Nanog-GFP+ colonies generated from OKSM-transduced MEFs 
(n = 3, P < 0.05; Supplementary Figure S5 and Supplementary 
Materials and Methods). In particular, bpV(HOpic)+VPA strongly 
enhanced the reprogramming efficiency by more than fourfold 
compared with that of bpV(HOpic) alone (12 ± 4 versus 48 ± 7; 
Supplementary Figure S5 ).
Next, we examined the characteristics of bpV-iPSCs. Bisulfite 
genomic sequencing analyses were performed to examine epigen-
etic modification of pluripotency-associated promoter regions 
such as Nanog and Oct3/4 genes.1,2,12,31 The promoters of Nanog 
and Oct3/4 genes in OKSM- and OKS-transduced bpV-iPSCs 
were less methylated than those in MEFs, which was similar to 
those in ESCs (Figure 3b and Supplementary Figure S6), sug-
gesting that similar DNA methylation patterns of pluripotency 
genes, such as Nanog and Oct3/4, stably maintained the undif-
ferentiated state of bpV-iPSCs.
In addition, karyotype analyses showed that the chromosomal 
status of bpV-iPSCs was normal over 15 passages (Supplementary 
Figure S7), indicating that transient activation of the PI3K path-
way by a Pten inhibitor, bpV(HOpic), did not affect chromosomal 
stability in the process of reprogramming.
Figure 2 Activation of the PI3K-Akt pathway enhances iPSC generation. (a) Counts of AP+ colonies formed by transduction of OKSM combined with 
the dominant-negative form of Pten (CS-Pten) or activated form of Akt (myr-Akt) into MEFs. Wild-type MEFs (1 × 105) were transduced with OKSM (con-
trol, left), OKSM+CS-Pten (middle), or OKSM+myr-Akt (right). Cells (5,000) were transferred onto SNL feeders on day 4 after transduction and cultured 
in ESC medium. AP+ colonies were counted on day 14 after transduction. Data are the mean ± SD (n = 3), *P < 0.05 versus control. (b) Experimental 
scheme for iPSC generation. MEFs (1 × 105) were infected with retroviruses carrying OKSM on day 0. Cells (5,000) were transferred onto SNL feeders on 
day 4 after transduction and cultured in ESC medium containing 100 nmol/l bpV(HOpic). Colonies were collected based on ESC-like morphology on 
day 14 after transduction. The Pten inhibitor bpV(HOpic) was added from day –1 to 10. (c) Counts of AP+ colonies formed by transduction of OKSM 
or OKS into MEFs in the presence of LY294002 or bpV(HOpic). A total of 5,000 (OKSM) or 50,000 (OKS) retrovirally transduced MEFs were transferred 
onto SNL feeders on day 4 after transduction and then cultured in the presence of 100 nmol/l bpV(HOpic) or 5 μmol/l LY294002 for 10 (OKSM) or 28 
days (OKS). AP+ colonies were counted on day 10 (OKSM, left panel) and day 28 (OKS, right panel). AP+ colonies generated without drugs were used 
as controls. Data are the mean ± SD (n = 3), *P < 0.05 versus controls. (d) Characteristics of bpV-iPSCs in vitro. The expression of ESC marker genes in 
bpV-iPSCs (OKSM) was examined by RT PCR (bpV-iPSC clones 1–8). Mouse β-actin was used as a loading control. The RT (−) control is shown at the 
bottom. (e) Representative images of bpV-iPSC colonies (left panel), AP staining (middle panel), and SSEA1 staining (right panel). Scale bars = 100 μm. 
ESC, embryonic stem cell; iPSC, induced pluripotent stem cell; MEF, mouse embryonic fibroblast; RT, reverse transcription.
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We next examined in vitro and in vivo differentiation potentials 
of bpV-iPSCs. bpV-iPSC differentiation was induced by embry-
oid body (EB) formation in vitro. Immunocytochemical analysis 
revealed that EB-formed cells expressed lineage markers of the 
ectoderm (β-III tubulin), mesoderm (α-smooth muscle actin), 
and endoderm (cytokeratin 8) (Figure 4a). We then performed 
a teratoma formation assay in vivo. One-million bpV-iPSCs were 
injected into the testes and backs of SCID mice. At 4–5 weeks after 
injection, we observed tumor formation. Histological analyses by 
hematoxylin-eosin staining showed that the tumors contained 
various derivatives of the three germ layers, indicating develop-
ment of a well-differentiated teratoma (Figure 4b). Moreover, 
bpV-iPSCs contributed to somatic tissue formation in chimeric 
mice and showed a germline transmission capability (Figure 4c). 
These results strongly indicated that bpV-iPSCs possessed pluri-
potency in vitro and in vivo.
Next, we attempted to elucidate the mechanisms that pro-
moted iPSC generation by the Pten inhibitor. We first examined 
the effect of bpV(HOpic) on the reprogramming time window 
by transduction of OKSM or OKS into Nanog-GFP MEFs. We 
found that the reprogramming time window was not affected by 
the addition of bpV(HOpic), although the number of GFP+ cells 
was increased on around day 10 (OKSM) and day 15 (OKS) after 
transduction (Figure 5a).
Figure 3 Addition of bpV(HOpic) improves the reprogramming of 
Nanog-GFP MEFs by OKSM or OKS. (a) Counts of Nanog-GFP+ colonies 
formed by transduction of OKSM or OKS into MEFs in the presence of 
LY294002 or bpV(HOpic). Nanog-GFP MEFs were retrovirally transduced 
with OKSM (left panel) or OKS (right panel) and then cultured in the pres-
ence of 5 μmol/l LY294002 or 100 nmol/l bpV(HOpic) for 9 days (from day 
5 to 14 after transduction, left panel) or 33 days (from day 5 to 38 after 
transduction, right panel). The number of GFP+ colonies was counted by 
observation under an immunofluorescence microscope. Data are the mean 
± SD (n = 12 for LY294002- or bpV(HOpic)-treated groups and n = 6 for the 
control group), *P < 0.05. (b) DNA methylation analysis of the promoter 
regions for endogenous Nanog and Oct3/4 genes. Genomic DNA from 
wild-type MEFs, mouse ESCs, wild-type iPSCs, and bpV-iPSCs (OKSM) were 
analyzed by bisulfite sequencing. Open and closed circles indicate unmeth-
ylated and methylated CpG islands, respectively. ESC, embryonic stem cell; 
iPSC, induced pluripotent stem cell; MEF, mouse embryonic fibroblast.
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Figure 4 Pluripotency of bpV-iPSCs. (a) In vitro differentiation ability 
of bpV-iPSCs. After EB formation for 7 days, EBs were transferred onto 
0.1% gelatin-coated dishes, cultured for another 6 days, fixed, and then 
processed for immunocytochemistry using antibodies against β-III tubulin 
(ectoderm marker, left panel), α-smooth muscle actin (mesoderm marker, 
middle panel), and cytokeratin 8 (endoderm marker, right panel). Scale 
bars = 50 μm. (b) In vivo differentiation ability of bpV-iPSCs. Hematoxylin-
eosin staining of tissue sections showing teratomas composed of mature 
tissues derived from the three embryonic germ layers. Magnification 
×200. (c) Contribution of bpV-iPSCs to chimeric mice. Injection of bpV-
iPSCs derived from ICR mice into C57BL/6 blastocysts led to the genera-
tion of chimeric mice (left panel). Offspring (chimera male × ICR female) 
were white, indicating germline transmission of bpV-iPSCs (right panel). 
iPSC, induced pluripotent stem cell.
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To further address how the efficiency of iPSC generation 
was enhanced by Pten inhibition, we examined cell death, cell 
cycle distribution, and proliferation affected by bpV(HOpic). 
Cell survival of OKSM- and OKS-transduced MEFs treated with 
bpV(HOpic) in the process of reprogramming was assessed using 
annexin V staining. We did not observe any significant increase 
or decrease in cell death induced by bpV(HOpic) at the indicated 
time points (Figure 5b), although cell death on day 4 after trans-
duction tended to be inhibited in the presence of bpV(HOpic). 
However, we found that the proliferation rate of OKSM- and 
OKS-transduced MEFs treated with bpV(HOpic) was slightly 
higher than that of the untreated control (Figure 5c), although the 
data from OKSM-transduced MEFs on day 7 after transduction 
showed no effect on proliferation induced by bpV(HOpic). These 
Figure 5 Effects of bpV(HOpic) on survival, proliferation, and reprogramming of MEFs. (a) Promotion of reprogramming by bpV(HOpic). 
Nanog-GFP MEFs were retrovirally transduced with OKSM (upper panel) or OKS (lower panel) and then cultured in the presence (black bar) or 
absence (white bar) of bpV(HOpic). The number of GFP+ cells was counted by observation under an immunofluorescence microscope at the indicated 
time points after transduction. Data are the mean ± SD (n = 3), *P < 0.05. (b) Analysis of cell death. OKSM- (left panel) or OKS- (right panel) trans-
duced MEFs were cultured with or without 100 nmol/l bpV(HOpic) for 4 or 7 days. The annexin V+ cell population was analyzed by flow cytometry. 
Data are the mean ± SD (n = 3). (c) Effects of bpV(HOpic) on cell proliferation. The number of OKSM- (left panel) or OKS- (right panel) transduced 
MEFs cultured with or without 100 nmol/l bpV(HOpic) for 4 or 7 days was counted. Data are the mean ± SD (n = 3), *P < 0.05. (d) Cell cycle analysis. 
OKSM- or OKS-transduced MEFs were cultured in the presence of 100 nmol/l bpV(HOpic) for 4 days, and then a BrdU assay was performed. MEFs 
and OKSM- or OKS-transduced MEFs without bpV(HOpic) treatment were used as controls. Data are the mean ± SD (n = 3). GFP, green fluorescent 
protein; MEF, mouse embryonic fibroblast.
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data indicated that bpV(HOpic) treatment slightly promoted cell 
proliferation, particularly during the early phase of reprogram-
ming of OKSM- and OKS-transduced MEFs. However, the cell 
cycle distribution was not changed significantly (Figure  5d). 
These results indicated that the enhancement of iPSC generation 
by Pten inhibition was associated with slightly accelerated cell 
proliferation during the early phase of reprogramming.
DISCUSSION
It is known that the efficiency of iPSC generation by retroviral 
transfer of reprogramming factors into MEFs is ~0.1–1%.1–4,6,7 In 
this study, we have developed a novel method that enhances the 
reprogramming efficiency of OKSM-transduced mouse somatic 
cells by transient activation of the PI3K pathway using a Pten 
inhibitor, bpV(HOpic). The efficiency of AP+ cell generation from 
OKSM-transduced MEFs by the addition of bpV(HOpic) was 
~7% (Figure 2c, left panel). This high proportion of AP+ cells was 
surprising, but there was a possibility that insufficiently repro-
grammed cells were included in the AP+ population. Therefore, 
we also examined the efficiency of SSEA1+ cell generation from 
MEFs. The proportion of SSEA1+ cells generated from OKSM-
transduced MEFs treated with bpV(HOpic) was ~3% (n = 3, P < 
0.05; Supplementary Figure S2), strongly suggesting the ability of 
bpV(HOpic) to enhance iPSC generation. It should also be noted 
that combined use of bpV(HOpic) with VPA further improved 
iPSC generation (Supplementary Figure S5b).
The mechanisms of bpV(HOpic) treatment, which increase 
the efficiency of iPSC generation, are considered to be crucial. 
We have shown that treatment with LY294002 from day 0 to 10 
after OKSM transduction inhibited the efficiency of iPSC genera-
tion (Figure 2c), whereas expression of the activated form of Akt 
(myr-Akt)-enhanced iPSC generation (Figure 2a). Thus, it is con-
ceivable that activation of the PI3K-Akt pathway due to inhibition 
of Pten by bpV(HOpic) at least in part plays a role in the repro-
gramming process.
Several molecules downstream of the PI3K-Akt pathway 
are responsible for critical biological phenomena such as self-
renewal, and cell survival and proliferation. It has been reported 
that c-Myc and its downstream target, cyclin D, are activated by 
the PI3K-Akt pathway,32 which leads to acceleration of the cell 
cycle. Another report has described that Akt inhibits cell cycle 
inhibitory molecules, p21 and p27.8,33 This evidence indicates that 
activation of the PI3K-Akt pathway promotes cell proliferation. 
Indeed, MEFs treated with bpV(HOpic) showed a slightly higher 
rate of proliferation (Figure 5b). Previous reports have described 
that promotion of cell proliferation results in the enhancement 
of iPSC generation.34 Thus, the acceleration of cell proliferation 
caused by the treatment with bpV(HOpic) may be associated with 
the activation of cell cycle molecules, which leads to the elevation 
of the efficiency of iPSC generation from somatic cells.
Several reports have shown that GSK3β is a key regulator 
of cellular fate and a participant in differentiation events dur-
ing embryonic development through the Wnt/GSK3β/β-catenin 
signaling pathway.35 Phosphorylation of GSK3β by Akt allows 
translocation of β-catenin into the nucleus, which activates tran-
scription factors such as c-Myc and Nanog and promotes repro-
gramming.29,36 Therefore, the use of bpV(HOpic) might inhibit 
GSK3β through activation of the PI3K-Akt pathway, resulting in 
the enhancement of iPSC generation.
Recently, treatment with 0.3 μmol/l LY294002, a PI3K pathway 
inhibitor, from day 1 to 3 after OKSM transduction was shown to 
enhance the efficiency of iPSC generation from MEFs.37 However, 
in our study, treatment with 5 μmol/l LY294002 from day 0 to 10 
after OKSM transduction inhibited the efficiency of iPSC genera-
tion (Figure 2c). The discrepancy between these data might be 
due to the difference in drug concentrations and/or the duration 
of drug treatment used for iPSC generation.
It has been reported that the efficiency of reprogramming is 
enhanced by increased cell proliferation and survival by inhibi-
tion of the p53-p21 pathway and Ink4a/Arf locus.8,33,34,38–42 Indeed, 
use of the p53 inhibitor pifithrin-α hydrobromide (PFTα) tended 
to show a higher reprogramming efficiency (Supplementary 
Figure  S8). However, p53 was slightly accumulated in OKSM-
transduced MEFs treated with bpV(HOpic) (Supplementary 
Figure S9), indicating that promotion of iPSC generation by 
bpV(HOpic) was not due to reduced p53 protein levels. Further 
investigation is needed to reveal the significance of slight p53 sta-
bilization in OKSM-transduced MEFs treated with bpV(HOpic).
Interestingly, for cell proliferation, previous reports have 
shown that mitochondrial oxidation is generally used in differ-
entiated somatic cells, whereas glycolysis is mainly used in plu-
ripotent cells.27,43 In addition, it has been shown that modulation 
of cell metabolism from mitochondrial oxidation to glycolysis 
plays an important role in the process of iPSC generation.27,43,44 
Because PI3K signaling is known to be a potent regulator of 
cellular metabolism,45 the possibility that inhibition of Pten by 
bpV(HOpic) induces a change of metabolic pathways from mito-
chondrial oxidation to glycolysis should also be carefully exam-
ined in the future.
Because continuous activation of the PI3K pathway causes 
transformation of cells,46 bpV(HOpic) treatment may cause the 
emergence of cancer cells. However, iPSCs generated in the presence 
of bpV(HOpic) could be readily and stably expanded over a long 
term under conventional ESC culture conditions (>15 pass ages) 
and exhibited a normal karyotype (Supplementary Figure  S7). 
Furthermore, they could directly differentiate into the three germ 
layers in vitro and formed teratomas in vivo. In mice, injection of 
these bpV-iPSCs into C57BL/6 host blastocysts resulted in the gen-
eration of healthy chimeric mice showing a germline transmission 
capability (Figure 4). Out of 11 chimeric mice aged over 1 year, 
nine mice did not survive owing to unknown reasons, and only one 
mouse formed a teratoma in the left leg (data not shown). Teratoma 
formation in a bpV-iPSC chimeric mouse might be influenced by 
reactivation of reprogramming factors or transient activation of 
the PI3K pathway in the process of reprogramming. In addition, 
some of the bpV-iPSCs injected into blastocysts might remain in an 
undifferentiated state. These possibilities need to be carefully con-
sidered when iPSC-based cell replacement therapies are conducted 
for regenerative medicine in the future.
MATERIALS AND METHODS
Plasmids. pMXs-based retroviral vectors for mouse Oct3/4, Klf4, Sox2, 
and c-Myc were obtained from Addgene (Cambridge, MA).47 pMXs vec-
tors encoding a mutant derivative of Pten containing a Cys-124 to serine 
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substitution (CS-Pten),22 myr-Akt, or GFP genes were gifts from Akira 
Suzuki (Kyushu University, Fukuoka, Japan).
Cell culture. PLAT-E cells for production of retroviruses were kindly provided 
by Dr. Toshio Kitamura (Tokyo University, Tokyo, Japan) and maintained in 
Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen, Carlsbad, CA) 
containing 10% fetal bovine serum (FBS; Invitrogen), 1 mg/ml puromycin 
(InvivoGen, San Diego, CA), and 10 μg/ml blasticidin S (InvivoGen).48 MEFs 
were isolated from pregnant mice at gestational day 12 (Crlj: CD1, Charles 
River, Japan; Nanog-GFP Mouse, Rikken, Japan) and expanded in fibroblast 
medium consisting of DMEM/10% FBS with 1% antibiotic-antimycotic 
mixed stock solution (Nacalai Tesque, Kyoto, Japan). Pten-deficient MEFs 
were kindly provided from Dr. Akira Suzuki (Kyushu University, Fukuoka, 
Japan).19 SNL feeders and MEFs were cultured in DMEM/10% FBS with 
antibiotics on 0.1% gelatin-coated dishes at 37 °C with 5% CO2. SNL feeders 
were treated with 12 μg/ml MMC (Kyowa Hakko Kirin, Tokyo, Japan) for 
around 2 hours before coculture with iPSCs. Mouse iPSCs were cultured on 
gelatin-coated plates with MMC-treated SNLs in mouse ESC medium con-
sisting of knockout DMEM containing 1000 U/ml leukemia inhibitory fac-
tor (Wako, Osaka, Japan), 2 mmol/l L-glutamine (Nacalai Tesque), 10% FBS, 
0.1 mmol/l 2-mercaptoethanol (Sigma-Aldrich, St Louis, MO), 1%  non-
essential amino acids (Invitrogen), and 50 IU/ml penicillin and 50 mg/ml 
streptomycin mixed solution (Nacalai Tesque).
Retrovirus production and iPSC generation. For retroviral production, 
PLAT-E cells were seeded at 3.3 × 106 cells per 100 mm dish. The follow-
ing day, 9 μg pMXs-based retroviral vectors for expression of GFP, Oct3/4, 
Klf4, Sox2, or c-Myc were individually introduced into PLAT-E cells using 
FuGENE 6 transfection reagent (Roche Diagnostics, Indianapolis, IN). After 
24 hours, the medium was replaced with 10 ml DMEM/10% FBS, and the 
supernatant was collected on the following day. On day 0, equal volumes 
of supernatants from PLAT-E cell cultures containing retroviruses carrying 
each factor were mixed, and then 1 × 105 (OKSM) − 1 × 106 (OKS) ICR-MEFs 
or 8 × 104 (OKSM) − 1 × 106 (OKS) Nanog-GFP MEFs were incubated with 
the mixture. At 4 days after infection, the cells were transferred onto MMC-
treated SNL feeders and cultured in ESC medium. Using 35-mm dishes, 
5,000 OKSM-transduced and 50,000 OKS-transduced cells were trans-
ferred onto SNL feeders. AP+ and SSEA1+ colonies were examined on day 
14 for OKSM-transduced cells, and on day 28 for OKS-transduced cells. To 
examine the efficiency of iPSC generation from single cell population, 100 
of OKSM-transduced cells or 100 of OKS-transduced cells were transferred 
onto MMC-treated SNL feeders on day 4 after transduction, and their AP 
activity was examined on days 14 (OKSM) and 28 (OKS), respectively.
Regulation of the PI3K-Akt pathway. To activate the PI3K-Akt pathway, 
MEFs were retrovirally transduced with a dominant-negative mutant type 
of Pten (CS-Pten)22 or activated form of myristoylated Akt (myr-Akt).23 
Moreover, to activate the PI3K-Akt pathway with the Pten inhibitor, MEFs 
were treated with bpV(HOpic) (100 nmol/l; Calbiochem, Darmstadt, 
Germany), bpV(Phen) (100 nmol/l; Calbiochem), SF1670 (500 nmol/l; 
Cellagen Technology, San Diego, CA), or PS48 (5 μmol/l; Wako). Then, to 
inhibit the PI3K-Akt pathway, cells were treated with LY294002 (5 μmol/l; 
Santa Cruz Biotechnology, Heidelberg, Germany).
AP staining. AP staining was performed using an Alkaline Phosphatase Kit 
(Sigma-Aldrich). Colonies grown in 35-mm dishes were fixed in a fixative 
solution for 30 seconds at room temperature and then washed twice with 
deionized water for 45 seconds. Fixed cells were incubated with the AP stain-
ing solution while protected from light for 1 hour at room temperature and 
then washed twice with deionized water for 2 minutes. The samples were 
then observed by optical microscopy (Axiovert 135; ZEISS, Deutschland, 
Germany).
Immunocytochemical staining. Cells were fixed with 4% paraformalde-
hyde in phosphate-buffered saline (PBS) for 30 minutes and then washed 
extensively with PBS. The cells were then permeabilized with 0.3% Triton 
X-100 in PBS for 5 minutes, followed by blocking with 3% bovine albumin 
serum in PBS. Staining was carried out by incubation with an anti-SSEA1 
antibody (Santa Cruz Biotechnology) overnight at 4 °C. After extensive 
washing, an antimouse Alexa546 antibody (Invitrogen) was applied for 1 
hour at room temperature, and then the cells were counterstained with 
4,6-diamindino-2-phenylindole-2 (Invitrogen). Images were obtained by 
immunofluorescence microscopy (BZ-9000, KEYENCE, Osaka, Japan).
Reverse transcription PCR.  Total RNA was extracted from cultured cells 
using an RNeasy kit (Qiagen, Courtaboeuf, France), and cDNA was syn-
thesized using a reverse transcription system (Invitrogen). PCR was per-
formed using KOD FX DNA polymerase (Toyobo, Tokyo, Japan) according 
to the manufacturer’s instructions. Primer sequences are described in 
Supplementary Tables S2 and S3. PCR products were size fractionated on 
1% agarose gels. β-actin was used as a loading control.
Bisulfite sequencing and karyotype analysis. Genomic DNA from 
mouse ESCs, MEFs, and bpV-iPSCs was extracted with a DNeasy Blood 
& Tissue Kit (Qiagen) and then treated with sodium bisulfite using a 
BisulFast DNA Modification Kit (Toyobo). Treated DNA was purified 
using an EZ kit (Zymo Research, Orange, CA). Then, Nanog and Oct3/4 
gene promoter regions49 were amplified by PCR using primers shown in 
Supplementary Table S4. PCR products were inserted into a pGEM-T 
easy vector (Promega, Madison, WI) and then sequenced using M13 prim-
ers. Karyotype analysis was performed at the ICLAS Monitoring Center, 
Central Institute for Experimental Animals.
Spontaneous differentiation in vitro and immunocytochemistry. The 
pluripotency of bpV-iPSCs was assessed by an in vitro differentiation assay. 
Briefly, single cells were harvested by trypsinization, and 1 × 106 cells were 
cultured on low adhesion plates in mouse ESC medium without leukemia 
inhibitory factor. Half medium volumes were exchanged every day, and EBs 
were allowed to grow for 6–7 days in suspension. Then, EBs were trypsin-
ized and replated onto 0.1% gelatin-coated dishes and cultured for another 
7 days (ectoderm) or 14 days (endoderm and mesoderm). Spontaneous 
differentiation was examined by immunocytochemistry using antibodies 
against cytokeratin 8 (Invitrogen), α-smooth muscle actin (Sigma, St Louis, 
MO), and β-III tubulin (Sigma). The samples were observed by immuno-
fluorescence microscopy (BZ-9000).
Teratoma formation assay. The bpV-iPSCs (1 × 106) were resuspended in 
50 μl PBS and then injected into the testis or back of SCID mice (Charles 
River Laboratories). At 4–8 weeks after injection, formed tumors were 
removed and fixed in 4% paraformaldehyde/PBS overnight at 4 °C. 
Tumor tissues were embedded in paraffin. Tissue blocks were sectioned 
at 3 μm and stained with hematoxylin-eosin. All animal experiments were 
approved by the Animal Committees at Kyushu University and Kumamoto 
University, Japan.
Generation of chimeric mice. To generate chimeric mice derived from 
bpV-iPSCs, C57BL/6 host blastocysts injected with bpV-iPSCs were trans-
planted into the uteri of surrogate ICR mice. Detailed protocols have been 
described before.50
Proliferation and cell death analyses. OKSM- or OKS-transduced MEFs 
(1 × 105) were cultured in DMEM/10% FBS with or without bpV(HOpic). 
On days 4 and 7, cells were harvested and counted with a TC10 automated 
cell counter (Bio-Rad, Hercules, CA) to determine the cell number. The 
cells were then stained with annexin V-APC (BD Pharmingen, San Diego, 
CA), and the population of annexin V+ dead cells was analyzed by flow 
cytometry (FACS Verse; BD Biosciences, San Jose, CA).
BrdU assay. The BrdU incorporation assay was performed with BrdU 
FLOW Kits according to the manufacturer’s instructions (BD Pharmingen). 
Briefly, OKSM- or OKS-transduced MEFs were cultured in the presence 
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of 10 μmol/l BrdU-labeling reagent (BD Pharmingen) for 1 hour. Then, 
the cells were harvested and dissociated into single cells with a trypsin/
EDTA solution (Nacalai Tesque). Single cells were fixed, permeabilized, 
and stained with antibodies against BrdU and 7-AAD, and then samples 
were analyzed by flow cytometry (FACS Verse).
Statistical analyses. Data were shown as the mean ± SD and analyzed 
for statistical significance by GraphPad Prism version 5.0d (GraphPad 
Software, San Diego, CA). For comparisons between groups, the data were 
analyzed using a t-test or one-way analysis of variance with Tukey’s mul-
tiple comparison. A value of P < 0.05 was considered as significant.
SUPPLEMENTARY MATERIAL
Figure S1. Effect of Pten inhibitor, bpV(HOpic) on Akt activation.
Figure S2. Number of SSEA1+ colonies generated from MEFs in the 
presence of bpV(HOpic).
Figure S3. Number of AP+ colonies generated in the presence of 
PDK1 activator, PS48, or Pten inhibitor, bpV(HOpic).
Figure S4. Effects of various Pten inhibitors on iPSC generation.
Figure S5. Enhanced efficiency of iPSC generation by combined use 
of bpV(HOpic) with various compounds.
Figure S6. DNA methylation analysis of the promoter regions of en-
dogenous Nanog and Oct3/4 genes in OKS-transduced iPSCs.
Figure S7. Karyotype analysis of OKSM-transduced bpV-iPSCs.
Figure S8. Effects of p53 and Pten inhibitors on iPSC generation.
Figure S9. p53 expression in MEFs treated with bpV(HOpic).
Table S1. Summary of established bpV-iPSC cell lines.
Table S2. Primers used for RT-PCR.
Table S3. Endogenous primers used for RT-PCR.
Table S4. Primers used for bisulfite sequencing.
Materials and Methods.
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